what bpc 157 does andrew huberman recommend How BPC-157 Works: 6 Healing Mechanisms Explained (2026) bpc 157 andrew huberman BPC-157

The convergence of NO and VEGF pathways in cardiovascular research contexts suggests applications beyond repair: BPC-157's eNOS-activating properties make it a pharmacological tool for investigating NO bioavailability in vascular disease models

The researchers concluded that short-term DSIP treatment is unlikely to be a major therapy for chronic insomnia, though it may have minor benefits

Reported side effects include mild nausea, fatigue, dizziness, and temporary injection site irritation

Originally engineered at Washington State University by the Harding lab and later licensed to M3 Biotechnology, Dihexa retains the angiotensin IV pharmacophore for AT4 receptor binding while incorporating N-hexanoyl and aminohexanoic acid modifications that confer metabolic stability and lipophilic BBB penetration